Streetbeat News

Corporate Responsibility

EBS

Emergent BioSolutions announced a restructuring plan expected to save approximately $80M annually once fully implemented. The associated costs are estimated to be between $18M-$21M, primarily incurred in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 9:06 pm

EBS

Emergent BioSolutions is implementing strategic operational changes to stabilize its financial position, which includes reducing its workforce by approximately 300 employees across all areas of the company.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 9:06 pm

DERM

Journey Medical Corporation (NASDAQ:DERM), a commercial-stage pharmaceutical company, announced the appointment of Joseph M. Benesch as Chief Financial Officer effective April 26, 2024. Benesch, who has over 25 years of experience in financial leadership within the pharmaceutical industry, has been serving as the Interim CFO since January 2023 and was the Corporate Controller before that. The company highlights his extensive experience as a valuable asset, especially in anticipation of the potential approval of DFD-29 for treating rosacea.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 8:54 pm

ELAB

Elevai Labs has announced the launch of two new subsidiaries, Elevai Biosciences and Elevai Skincare, to expand its operations and offerings in the biosciences and skincare sectors.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 8:41 pm

FRSH

Freshworks has announced the appointment of Dennis Woodside as CEO and President, effective immediately. Woodside, who was already serving as President, will take over from Girish Mathrubootham, the company's founder. Mathrubootham will transition to the role of Executive Chairman. This leadership change is significant for Freshworks as it moves forward.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 8:19 pm

FRSH

Freshworks shares are trading lower following the announcement of Q1 financial results and a CEO transition.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 8:16 pm

BODY

The Beachbody Company announced an initiative allowing qualifying patients to use pre-tax HSA or FSA funds for BODi and Dr. B fitness solutions, aiming to save time and money.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 8:15 pm

AFL

Aflac's President and CEO, Daniel Amos, announced expectations for sales campaigns around the company's 50th anniversary in Japan starting in Q2 to help get the company back on track for the year.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 8:15 pm

AMPH

AZN

NVO

NVS

TEVA

The FTC is targeting 'junk patent listings' for drugs like Novo Nordisk's Ozempic and AstraZeneca's treatments to promote generic competition and reduce drug prices. The FTC issued warning letters to 10 companies, including Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Novartis, Amphastar Pharmaceuticals, and Teva Pharmaceutical, disputing over 300 Orange Book patent listings to facilitate the availability of affordable alternatives.

Portfolio Pulse from Vandana Singh

May 01, 2024 | 8:11 pm

KMPR

Kemper Corporation (NYSE:KMPR) announced Gerald Laderman as the new Chairman of the Board, succeeding Joseph P. Lacher, Jr., who remains CEO, President, and Director. Laderman, with a background in the airline industry and roles at United Airlines and Continental Airlines, joined Kemper's board in 2020. The company highlighted his leadership skills and expressed confidence in the ongoing strategy under Lacher's leadership.

Portfolio Pulse from Benzinga Newsdesk

May 01, 2024 | 8:09 pm